Floatz logo

rft5-smpt-dga

Hodgkin Disease

National Heart, Lung, and Blood Institute (NHLBI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB

View all 50 →

Same molecule, other indications

rft5-smpt-dga is also rated in:

graft versus host diseaseDormant
B
Indicative ·
57 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
chronic myelomonocytic leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →